POSB63 Analysis of Cost per PASI75 and per Dlqi 0/1 Responder over 52 WEEKS in Patients with Moderate Plaque Psoriasis Initiated on Apremilast, Remaining on Apremilast or Switching to Biologics, and Patients Hypothetically Treated with Biologics AB Initio, Based on the Results of the Apraisal Multicenter Observational Study in Greece

Elena Sotiriou ,Z Anagnostopoulos,Kd Tomai,A Kekki,Konstantinos Krasagakis ,Natalia Rompoti ,P Aronis ,Alexandros A Drosos ,Evangelia Rovithi ,Evangelia Papadavid ,Elizabeth Lazaridou ,A Protopapa ,Efthymia Gialeli ,E Pokas ,Nikolaos Antonakopoulos ,John Katsantonis ,Marina Papageorgiou ,I Lefaki ,O Neofotistou ,Christina Kalinou ,Konstantina Mavridou ,Efterpi Zafiriou ,Vasiliki Chasapi ,Markos Papakonstantis

doi:10.1016/j.jval.2021.11.336

POSB63 Analysis of Cost per PASI75 and per Dlqi 0/1 Responder over 52 WEEKS in Patients with Moderate Plaque Psoriasis Initiated on Apremilast, Remaining on Apremilast or Switching to Biologics, and Patients Hypothetically Treated with Biologics AB Initio, Based on the Results of the Apraisal Multicenter Observational Study in Greece

Elena Sotiriou , Z Anagnostopoulos + Show 22 more

Open Access

https://doi.org/10.1016/j.jval.2021.11.336

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Jan 1, 2022
License type: elsevier-specific: oa user license

Affiliation: Aristotle University of Thessaloniki, University Hospital of Heraklion, National and Kapodistrian University of Athens, Hellenic Airforce General Hospital, General Hospital of Attica, The General Hospital of Heraklion "Venizeleio-Pananio", General University Hospital of Patras, Tzaneion General Hospital, Hospital Venereal and Skin Diseases Thessaloniki, Euromedica, Agia Olga Hospital, Agios Pavlos General Hospital, University of Ioannina, University Hospital of Larissa, Andreas Sygros Hospital, 401 General Military Hospital of Athens

#Cost-per-responder #Psoriasis Area Severity Index + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The 52-week treatment cost per patient achieving ≥75% reduction in Psoriasis Area Severity Index [PASI75 cost-per-responder (CPR)] and per patient attaining Dermatology Life Quality Index (DLQI) 0/1 (DLQI-0/1 CPR) was estimated in patients initiated and remaining on apremilast (APR) or switching to biologics, and patients hypothetically treated with biologics ab initio.

Full Text